Press Release: Novartis provides update on -2-

References

1. ClinicalTrials.gov. Available

at: https://clinicaltrials.gov/study/NCT06411288. Accessed August 2026.

2. Duong T, de Monts C, McIntyre M, et al. 444P Exploring hand myotonia:

assessing hand opening and individual finger movements through machine

learning. Neuromuscular Disorders. 2024;43(Suppl 1):104441.

3. Muscular Dystrophy Association. Myotonic Dystrophy (DM). Available

at: https://www.mda.org/disease/myotonic-dystrophy. Accessed August 2026.

4. Kwan TT, Meng Q, Delos Santos N, et al. Delpacibart etedesiran improves

the molecular pathology of myotonic dystrophy type 1 in the phase 1/2

MARINA study. Molecular Therapy.

2026;34(5). doi:10.1016/j.ymthe.2026.03.013.

5. National Human Genome Research Institute. About Myotonic Dystrophy.

Available

at: https://www.genome.gov/Genetic-Disorders/Myotonic-Dystrophy. Accessed

August 2026.

6. Johnson NE, Tai LJ, Hamel JI, et al. An antibody-oligonucleotide

conjugate for myotonic dystrophy type 1. N Engl J Med. 2026;394:717-730.

PMID: 41707138.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

September 08, 2026 01:00 ET (05:00 GMT)